Iqvia Holdings, Inc. · NYSE:IQV

Iqvia — Quintiles — Raymond James 37th Annual Institutional Investors Conference (March 2016)

15 slides from Iqvia's conference presentation, Mar 7, 2016

  1. Slide 1: Raymond James 37th Annual Institutional Investors Conference

    Raymond James 37th Annual Institutional Investors Conference Tom Pike CEO March 7, 2016 © Copyright 2016 Quintiles NYSE: Q

  2. Slide 2: Forward Looking Statements and Use of Non-GAAP Financial Measures

    Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements refl

  3. Slide 3: Enterprise Vision and Strategy

    Enterprise Vision and Strategy Quintiles We bring people and knowledge Vision together for a healthier world. Biopharma Our Customer Promise Integrated Product Healthcare Development Services Excellence at Global People, Process & Technology Scientific, Quantitative Therapeutic & & Analytical Rx Exp

  4. Slide 4: Attractive and Growing Market

    Attractive and Growing Market ~$200bn total market across both segments with increasing outsourcing penetration which drives estimated growth of 6% – 8% per year from 2015 – 2018 Approval Phase Commercial Phase I Phase II Phase III Healthcare Delivery IV Product Development Services Integrated Healt

  5. Slide 5: Deep Therapeutic, Domain, & Regulatory Expertise Across Fast-Growing Therapy Areas

    Deep Therapeutic, Domain, & Regulatory Expertise Across Fast-Growing Therapy Areas Our resources provide competitive advantage, breadth of offerings, & ability to innovate Apply knowledge & services across Ability to serve the diverse needs of therapy areas our biopharma customers Therapeutic Center

  6. Slide 6: Quintiles' Global Delivery Network Extends Our Industry Leadership Position

    Quintiles’ Global Delivery Network (GDN) Extends Our Industry Leadership Position Strategically leverages our global presence… …and drives quality, efficiency, & productivity Source top talent around the world Strategically manage peaks and troughs of supply and demand in key nodes Standardize proce

  7. Slide 7: Integrated Data Assets Combine Our Deep Expertise and Global Scale

    Integrated Data Assets Combine Our Deep Expertise and Global Scale Data Integration is key to unlocking the productivity puzzle Clinical research data collected across 487 indications Access to >61M patient lives in 18 therapeutic areas via Electronic Health Records from >175,000 providers since 200

  8. Slide 8: Why Quintiles? The integration of our assets creates differentiated value

    Why Quintiles? The integration of our assets creates differentiated value Global harmonized Deep therapeutic, domain, & best in class Technology & informatics regulatory expertise processes & workforce >1,100 >24 Quintiles Infosario® Platform Medical doctors Prime sites Planning & Design Global Safe

  9. Slide 9: Track Record of Profitable Growth and Consistency

    Track Record of Profitable Growth and Consistency Long-term performance underpinned with a diversified customer portfolio Service Revenues Adjusted EBITDA(1) ’11 – ’15 CAGR = 7.0% ’11 – ’15 CAGR = 13.7% $819 4,400 $4,326 800 $4,166 $725 $3,692 $3,808 $3,295 $606 3,300 600 $546 $490 $ Millions $ Mill

  10. Slide 10: 2015 Financial Highlights

    2015 Financial Highlights Constant Currency Revenue  1.23x Book-to-bill ratio 9.0% Growth(1) • 1.29x in Product Development • 7.2% in Product Development • 1.06x in IHS • 14.0% in IHS  Completion of $2.75B debt refinancing • Extends maturities and lowers average cost of debt Diluted Adjusted EPS 2

  11. Slide 11: Quintiles: A differentiated market leader

    Quintiles A differentiated market leader Strong free cash flow Largest backlog in industry Consistent long Geographically term financial diversified revenue base performance First mover advantage with Clinical Development Successful M&A Informatics technology and JV track record Market leader in Pro

  12. Slide 12: Appendix

    Appendix QUINTILES’ 12

  13. Slide 13: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation Adjusted EBITDA Reconciliation Year Ended December 31 (In Thousands) 2011 2012 2013 2014 2015 Adjusted EBITDA: Net Income Attributable to Quintiles Transnational Holdings Inc. $241,772 $177,546 $226,591 $356,383 $387,205 Interest Expense, Net 105,126 131,304 119,571 97

  14. Slide 14: 2015 Constant Currency Reconciliation

    2015 Constant Currency Reconciliation Service Revenues and Income from Operations (millions of dollars) Three Months Ended December 31 Year on Year Growth Exchange Exchange Consolidated Actual Impact Constant Actual Impact Constant Service Revenues $ 1,128.6 $ (35.5) $ 1,164.1 6.1% (3.3%) 9.4% Incom

  15. Slide 15: Reconciliation of Net Income to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS

    Reconciliation of Net Income Attributable to Quintiles to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS Three Months Ended December 31 Year Ended December 31 (millions of dollars) 2015 1 2014 1 2015 1 2014 1 EPS EPS EPS EPS Net Income Attributable to Quintiles $ 104.6 $ 0.85 $ 88.4 $ 0.69 $

Quintiles — Raymond James 37th Annual Institutional Investors Conference (March 2016) on 6ix